Recent Blog Posts

View Post: Orphan drug designation granted to voreloxin for acute myeloid ...
5 Nov 2009
Sunesis Pharmaceuticals was granted orphan drug designation by the FDA for its drug candidate, voreloxin for the treatment of acute myeloid leukemia (AML). ... Elitek (rasburicase, from sanofi-aventis), a recombinant urate oxidase enzyme, has been approved for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: symptoms of acute myeloid leukemia - Health Resources - Health ...
9 Oct 2009 by Tiny  
Acute Myeloid Leukemia (Adult) - Symptoms, Treatment and Prevention . at diagnosis of acute myeloid leukemia is 65 . There are very few hereditary causes of acute myeloid leukemia. . Symptoms of Acute Myeloid Leukemia (Adult) . -> ...
View Blog: Health Resources - http://www.health-res.com/

---

View Post: Targeted treatment of acute myeloid leukemia in older adults: role of
27 Oct 2009
Abstract: As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower ...
View Blog: Clinical Interventions in Aging - http://www.dovepress.com/clinical-interventions-in-aging-journal

---

View Post: Leukemia Clinical Trial: Donor Stem Cell Transplant After Total ...
14 Oct 2009
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission .... irradiated cellular therapy; No known active brain metastases or malignant meningitis; Available partially (≥ 3/6 class I antigen) HLA-matched (by serology) related donor; NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...

---

View Post: Pathology Mcqs Postgraduation Entrance preparation: 27 - Chronic ...
17 Oct 2009 by prashanthparigela@gmail.com (doctor)  
Myeloid markers in blast cells: Blastic cells in myeloid CML blast phase closely resemble acute myeloid leukemia (AML), and blast cells express myeloid markers such as CD13, CD33, and CD117. Myeloperoxidase staining may be strongly or weakly positive or ... Juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, chronic eosinophilic leukemia, and other Ph positive leukemias (acute precursor B-cell lymphoblastic leukemia, adult AML. Posted by doctor at 5:11 AM ...
View Blog: Pathology Mcqs Postgraduation Entrance preparation - http://ourpathology.blogspot.com/

---

View Post: Research and Markets: Stakeholder Insight: Acute Leukemias ...
27 Oct 2009
The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, ...
View Blog: Latest Clinical Research Jobs - http://www.pharmiweb.com/

---

View Post: ASH 2006: Advances in Acute Myeloid Leukemia: Introduction
16 Mar 2007
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-7239. ...
View Blog: Medscape Headlines - http://www.medscape.com/home

---

View Post: ISPUB - Adult Haematooncology Cases: A Six Year Review At Lagos ...
12 Jul 2009
Heamato-oncology could be broadly classified into four groups, namely; Acute leukemia {consisting of Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Myelodysplastic syndrome}. Myeloproliferative disorders {consisting of Chronic ...
View Blog: Internet Scientific Publications - http://www.ispub.com/

---

View Post: World Pharma News - Novartis drug Tasigna® meets primary endpoint ...
20 Oct 2009
Tasigna produced faster and deeper responses than Glivec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. .... In the EU, Glivec is also approved for the treatment of adult patients with newly diagnosed Ph+ acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy and as a single agent for patients with relapsed or refractory Ph+ ALL. ...
View Blog: World Pharma News - http://www.worldpharmanews.com/

---